## Mouhab Ayas

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5143384/publications.pdf Version: 2024-02-01



Μομμλε Δγλς

#	Article	IF	CITATIONS
1	Allogeneic hematopoietic stem cell transplantation in Fanconi anemia: the European Group for Blood and Marrow Transplantation experience. Blood, 2013, 122, 4279-4286.	1.4	176
2	Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Dyskeratosis Congenita. Biology of Blood and Marrow Transplantation, 2013, 19, 1238-1243.	2.0	108
3	Hematopoietic stem cell transplantation for infantile osteopetrosis. Blood, 2015, 126, 270-276.	1.4	89
4	Allogeneic Hematopoietic Cell Transplantation for Fanconi Anemia in Patients With Pretransplantation Cytogenetic Abnormalities, Myelodysplastic Syndrome, or Acute Leukemia. Journal of Clinical Oncology, 2013, 31, 1669-1676.	1.6	69
5	Thiamineâ€responsive myelodysplasia. British Journal of Haematology, 1998, 102, 1098-1100.	2.5	50
6	Effect of antithymocyte globulin source on outcomes of bone marrow transplantation for severe aplastic anemia. Haematologica, 2017, 102, 1291-1298.	3.5	38
7	Influence of Age on Acute and Chronic GVHD in Children Undergoing HLA-Identical Sibling Bone Marrow Transplantation for Acute Leukemia: Implications for Prophylaxis. Biology of Blood and Marrow Transplantation, 2018, 24, 521-528.	2.0	34
8	Outcome of patients with Fanconi anemia developing myelodysplasia and acute leukemia who received allogeneic hematopoietic stem cell transplantation: A retrospective analysis on behalf of <scp>EBMT</scp> group. American Journal of Hematology, 2020, 95, 809-816.	4.1	30
9	The Saudi Experience in Fludarabine-Based Conditioning Regimens in Patients with Fanconi Anemia Undergoing Stem Cell Transplantation: Excellent Outcome in Recipients of Matched Related Stem Cells but Not in Recipients of Unrelated Cord Blood Stem Cells. Biology of Blood and Marrow Transplantation. 2012. 18. 627-632.	2.0	29
10	Factors Affecting the Outcome of Related Allogeneic Hematopoietic Cell Transplantation in Patients with Fanconi Anemia. Biology of Blood and Marrow Transplantation, 2014, 20, 1599-1603.	2.0	28
11	Transplant Outcomes for Children with T Cell Acute Lymphoblastic Leukemia in Second Remission: A Report from the Center for International Blood and Marrow Transplant Research. Biology of Blood and Marrow Transplantation, 2015, 21, 2154-2159.	2.0	25
12	Factors Associated with Long-Term Risk of Relapse after Unrelated Cord Blood Transplantation in Children with Acute Lymphoblastic Leukemia in Remission. Biology of Blood and Marrow Transplantation, 2017, 23, 1350-1358.	2.0	25
13	Successful Outcome in Patients with Fanconi Anemia Undergoing T Cell-Replete Mismatched Related Donor Hematopoietic Cell Transplantation Using Reduced-Dose Cyclophosphamide Post-Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 2217-2221.	2.0	25
14	Transplantation Outcomes for Children with Hypodiploid Acute Lymphoblastic Leukemia. Biology of Blood and Marrow Transplantation, 2015, 21, 1273-1277.	2.0	24
15	Low Body Mass Index Is Associated with Increased Risk of Acute GVHD after Umbilical Cord Blood Transplantation in Children and Young Adults with Acute Leukemia: A Study on Behalf of Eurocord and the EBMT Pediatric Disease Working Party. Biology of Blood and Marrow Transplantation, 2018, 24, 799-805.	2.0	22
16	Myelodysplastic syndrome evolving from aplastic anemia treated with immunosuppressive therapy: efficacy of hematopoietic stem cell transplantation. Haematologica, 2014, 99, 1868-1875.	3.5	19
17	Chimerism Analysis of Cell-Free DNA in Patients Treated with Hematopoietic Stem Cell Transplantation May Predict Early Relapse in Patients with Hematologic Malignancies. Biotechnology Research International, 2016, 2016, 1-6.	1.4	17
18	Hematopoietic stem cell transplantation corrects WIP deficiency. Journal of Allergy and Clinical Immunology, 2017, 139, 1039-1040.e4.	2.9	17

Моинав Ауаз

#	Article	IF	CITATIONS
19	Metastatic Ewing sarcoma/PNET of bone at diagnosis: Prognostic factors?a report from Saudi Arabia. Medical and Pediatric Oncology, 2001, 37, 383-389.	1.0	16
20	Clinical course and outcomes of COVIDâ€19 in hematopoietic cell transplant patients, a regional report from the Middle East. Bone Marrow Transplantation, 2021, 56, 2144-2151.	2.4	16
21	Second Stem Cell Transplantation in Patients with Fanconi Anemia Using Antithymocyte Globulin Alone for Conditioning. Biology of Blood and Marrow Transplantation, 2008, 14, 445-448.	2.0	14
22	Haploâ€identical or mismatched unrelated donor hematopoietic cell transplantation for <scp>Fanconi</scp> anemia: Results from the <scp>Severe Aplastic Anemia Working Party</scp> of the <scp>EBMT</scp> . American Journal of Hematology, 2021, 96, 571-579.	4.1	14
23	Prevalence of hereditary cancer susceptibility syndromes in children with cancer in a highly consanguineous population. Cancer Epidemiology, 2018, 55, 88-95.	1.9	13
24	Incidence, clinical distribution, and patient characteristics of childhood cancer in Saudi Arabia: A populationâ€based analysis. Pediatric Blood and Cancer, 2019, 66, e27684.	1.5	13
25	Hematopoietic cell transplantation in Fanconi anemia and dyskeratosis congenita: A minireview. Hematology/ Oncology and Stem Cell Therapy, 2017, 10, 285-289.	0.9	12
26	Congenital sideroblastic anaemia successfully treated using allogeneic stem cell transplantation. British Journal of Haematology, 2001, 113, 938-939.	2.5	11
27	Genetic and clinical characteristics of pediatric patients with familial hemophagocytic lymphohistiocytosis. Blood Research, 2021, 56, 86-101.	1.3	11
28	In cyclosporine induced neurotoxicity, is tacrolimus an appropriate substitute or is it out of the frying pan and into the fire?. Pediatric Blood and Cancer, 2008, 50, 426-426.	1.5	10
29	Hematopoietic stem cell transplant for hyperâ€lgM syndrome due to <scp>CD</scp> 40L defects: A singleâ€center experience. Pediatric Transplantation, 2015, 19, 634-639.	1.0	10
30	Second Allogeneic Hematopoietic Cell Transplantation for Patients with Fanconi Anemia and Bone Marrow Failure. Biology of Blood and Marrow Transplantation, 2015, 21, 1790-1795.	2.0	9
31	Hematopoietic stem cell transplantation in Saudi Arabia between 1984 and 2016: Experience from four leading tertiary care hematopoietic stem cell transplantation centers. Hematology/ Oncology and Stem Cell Therapy, 2021, 14, 169-178.	0.9	9
32	Allogeneic hematopoietic stem cell transplantation in leukocyte adhesion deficiency type I and III. Blood Advances, 2021, 5, 262-273.	5.2	9
33	Impact of autologous blood transfusion after bone marrow harvest on unrelated donor's health and outcome: a CIBMTR analysis. Bone Marrow Transplantation, 2020, 55, 2121-2131.	2.4	7
34	Does Mixed Chimerism After Allogeneic Hematopoietic Cell Transplantation in Pediatric Patients With Fanconi Anemia Impact on Outcome?. Transplantation and Cellular Therapy, 2021, 27, 257.e1-257.e6.	1.2	6
35	The outcome of children with acute myeloid leukemia (AML) post-allogeneic stem cell transplantation (SCT) is not improved by the addition of etoposide to the conditioning regimen. Pediatric Blood and Cancer, 2006, 47, 926-930.	1.5	5
36	Outcome of allogeneic stem cell transplantation with a conditioning regimen of busulfan, cyclophosphamide and low-dose etoposide for children with myelodysplastic syndrome. Hematology/ Oncology and Stem Cell Therapy, 2011, 4, 121-125.	0.9	5

Моинав Ауаз

#	Article	IF	CITATIONS
37	T-cell replete haploidentical transplantation with reduced post-transplant cyclophosphamide in six children with infantile osteopetrosis. Bone Marrow Transplantation, 2021, 56, 1757-1760.	2.4	5
38	Hematopoietic Stem Cell Transplantation Stabilizes Cerebral Vasculopathy in High-Risk Pediatric Sickle Cell Disease Patients: Evidence From a Referral Transplant Center. Journal of Hematology (Brossard,) Tj ETQq0 0	0 r <b>g.B</b> T /O	verbock 10 Tf !
	Successful hematopoietic cell transplantation in Fanconi anemia patients with renal impairment using		

39	ultraâ€reduced doses of cyclophosphamide and fludarabine. Pediatric Blood and Cancer, 2018, 65, e27371.	1.5	4
40	Prevalence and risk factors of oral mucositis in paediatric patients undergoing haematopoietic stem cell transplantation. Oral Diseases, 2022, 28, 657-669.	3.0	4
41	COVID-19 in Children Following Hematopoietic Cell Transplantation: A Multinational Study of the European Bone Marrow Transplantation Society (EBMT) and the Spanish Group of Hematopoietic Stem Cell Transplantation (GETH). Blood, 2021, 138, 2866-2866.	1.4	4
42	HLA-haploidentical donor transplants with post-transplant cyclophosphamide in children with primary immune deficiency disorders. Bone Marrow Transplantation, 2022, 57, 668-670.	2.4	4
43	Outcome of second allogenic stem cell transplantation in pediatric patients with nonâ€malignant hematological and immune deficiency disorders. Pediatric Blood and Cancer, 2011, 56, 289-293.	1.5	3
44	Frequency of pathogenic/likely pathogenic germline variants in cancerâ€related genes among children with acute leukemia in Saudi Arabia. Pediatric Blood and Cancer, 2020, 67, e28340.	1.5	3
45	Unrelated Hematopoietic Cell Transplantation in Aplastic Anemia. JAMA Oncology, 2015, 1, 1164.	7.1	1
46	Outcome of hematopoietic stem cell transplantation (HCT) from HLA-matched related donor for Fanconi anemia (FA) in adolescents and adults: a retrospective study by Eastern Mediterranean Blood and Marrow Transplantation Group (EMBMT). Bone Marrow Transplantation, 2020, 55, 1485-1490.	2.4	1
47	Experience of treating pediatric hepatoblastoma at King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia – Timely surgical intervention playing a key role. International Journal of Pediatrics and Adolescent Medicine, 2021, 8, 39-43.	1.2	1
48	Pediatric high risk neuroblastoma with autologous stem cell transplant – 20 years of experience. International Journal of Pediatrics and Adolescent Medicine, 2021, 8, 253-257.	1.2	1
49	Graft Versus Host Disease Following HLA-Matched Sibling Donor Compared with Matched Related Donor for Hematopoietic Stem Cell Transplantation for the Treatment of Severe Combined Immunodeficiency Disease. Journal of Clinical Immunology, 2019, 39, 414-420.	3.8	0
50	Unique aspects of Graft-versus-host-disease management in the Eastern Mediterranean region: Report from the Eastern Mediterranean blood and marrow transplantation group: Special report. Hematology/ Oncology and Stem Cell Therapy, 2020, , .	0.9	0
51	The AG Genotype of the Wilms Tumor-1 rs16754 SNP Is Associated with Poor Outcome in Pediatric AML Patients Treated with Stem Cell Transplantation but Not in Adults. Blood, 2011, 118, 5237-5237.	1.4	0
52	CD11b Expression Is An Independent Adverse Prognostic Factor in Pediatric Acute Myeloid Leukemia Treated with Allogeneic Stem Cell Transplantation,. Blood, 2011, 118, 4092-4092.	1.4	0
53	Outcome Of Hematopoietic Cell Transplantation (HCT) In Pediatric Patients With Non-Hodgkin Lymphoma (NHL): Single Institution Results From Saudi Arabia. Blood, 2013, 122, 5522-5522.	1.4	0
54	Impact of GvHD and Other Patient-, Disease-, Donor and Transplantation-Related Factors on 5 Year Relapse after Unrelated Cord Blood Transplantation for Children with Acute Lymphoblastic Leukemia in Remission. Blood, 2015, 126, 4384-4384.	1.4	0

#	Article	IF	CITATIONS
55	Prevalence of hereditary cancer susceptibility syndromes in children: A report from the Saudi Arabian Pediatric Hematology Oncology Society Journal of Clinical Oncology, 2016, 34, e13086-e13086.	1.6	0
56	Travel burden and geographic access to health care among children with cancer in Saudi Arabia. Eastern Mediterranean Health Journal, 2020, 26, 1355-1361.	0.8	0